Announced
Financials
Sources
Tags
Private
Pending
Croatia
biotechnology
Friendly
Acquisition
Majority
contract research organization
Biotechnology
Cross Border
Single Bidder
Test Inspection and Certification (TIC)
Synopsis
Selvita, an integrated service provider supporting customers and projects within area of drug discovery, regulatory studies, as well as research and development, agreed to acquire Fidelta, a contract research organization, from Galapagos,a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines, for $38m. “With this acquisition, we are not only executing our strategy announced this year, but we’re actually taking a leap in both the scope of our services portfolio and the scale of business. It is a transformative moment in the history of Selvita," Boguslaw Sieczkowski, Selvita CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.